Longitudinal association between endothelial dysfunction, inflammation, and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: An evaluation of the DCCT/EDIC cohort

Diabetes Care

Volumn 38, Issue 7, 2015, Pages 1281-1289

  Hunt, Kelly J ^a,b   Baker, Nathaniel L ^a   Cleary, Patricia A ^c   Klein, Richard ^a,b   Virella, Gabriel ^a   Lopes Virella, Maria F ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; SERPINE1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; THROMBOSIS; BLOOD; BLOOD CLOTTING; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ADULT; ATHEROSCLEROSIS; BIOMARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84947446217     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2877     Document Type: Article

References (44)

1. Costacou T, Lopes-Virella MF, Zgibor JC, et al, .; The Pittsburgh Epidemiology of Diabetes Complications Study. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. J Diabetes Complications 2005;19:183-193
2. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774-779
3. Hayaishi-Okano R, Yamasaki Y, Katakami N, et al. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care 2002;25:1432-1438
4. Huvers FC, De Leeuw PW, Houben AJ, et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999;48:1300-1307
5. Klein RL, Hunter SJ, Jenkins AJ, et al, .; DCCT/ECIC STUDY GROUP. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003;26:1439-1448
6. Lin J, Hu FB, Rimm EB, Rifai N, Curhan GC. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int 2006;69:336-342
7. Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 1996;81:485-490
8. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-325
9. Schram MT, Stehouwer CD. Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome. Horm Metab Res 2005;37(Suppl. 1):49-55
10. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005;22:999-1004
11. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G. Low risk of overt nephropathy after 24 yr of childhood-onset type 1 diabetes mellitus (T1DM) in Norway. Pediatr Diabetes 2006;7:239-246
12. Shai I, Schulze MB, Manson JE, et al. A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 2005;28:1376-1382
13. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370-378
14. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, Stehouwer CD, Ebeling P, Fuller JH; EURODIAB Prospective Complications Study group. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients. J Diabetes Complications 2006;20:188-195
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
16. Epidemiology of Diabetes Interventions and Complications (EDIC). Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
17. Nathan DM, Lachin J, Cleary P, et al, .; Diabetes Control and Complications Trial, ; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-2303
18. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999;48:383-390
19. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267-2271
20. Steffes M, Cleary P, Goldstein D, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem 2005;51:753-758
21. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(Suppl.):823-833
22. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130
23. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G; DCCT/EDIC Research Group. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care 2013;36:2317-2323
24. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-1437
25. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-494
26. O'Leary DH, Polak JF, Wolfson SK Jr, et al, .; CHS Collaborative Research Group. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. Stroke 1991;22:1155-1163
27. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991;134:250-256
28. Bots ML, Witteman JC, Grobbee DE. Carotid intima-media wall thickness in elderly women with and without atherosclerosis of the abdominal aorta. Atherosclerosis 1993;102:99-105
29. O'Leary DH, Polak JF, Kronmal RA, et al, .; The CHS Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke 1992;23:1752-1760
30. Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997;28:2442-2447
31. Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med 1988;112:1018-1031
32. Lorenz MW, Polak JF, Kavousi M, et al, .; PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012;379:2053-2062
33. Lopes-Virella MF, Carter RE, Gilbert GE, et al, .; Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort Study Group. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008;31:2006-2012
34. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695
35. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045-2051
36. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
37. Lopes-Virella MF, McHenry MB, Lipsitz S, et al, .; DCCT/EDIC Research Group. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007;190:359-369
38. Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G; DCCT/EDIC Research Group. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis 2011;214:462-467
39. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011;60:582-589
40. Hammad SM, Twal WO, Barth JL, et al. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 2009;202:394-404
41. Sherwood TA, Virella G. The binding of immune complexes to human red cells: complement requirements and fate of the RBC-bound IC after interaction with human phagocytic cells. Clin Exp Immunol 1986;64:195-204
42. Lappalainen J, Lindstedt KA, Oksjoki R, Kovanen PT. OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells. Atherosclerosis 2011;214:357-363
43. Virella G, Atchley D, Koskinen S, Zheng D, Lopes-Virella MF; DCCT/EDIC Research Group. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002;105:81-92
44. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006;47:1975-1983